Lv5
1070 积分 2022-04-22 加入
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma
23天前
已完结
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
26天前
已完结
A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity
1个月前
已完结
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
1个月前
已完结
Structural insights into IL-31 signaling inhibition by a neutralizing antibody
1个月前
已完结
Bispecific antibodies
1个月前
已完结
Multispecific T-cell engagers attract cancer drug developers
1个月前
已完结
Recent advances in antibody optimization based on deep learning methods
1个月前
已完结
Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions
2个月前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
2个月前
已完结
皖公网安备34019202002308
